Are Glaxo's China sales reforms putting it at a commercial disadvantage?

Since Chinese officials slapped GlaxoSmithKline ($GSK) with a $489 million fine on bribery charges, the company has overhauled its sales practices to quash corruption there. But some in the industry say its reforms--which include eliminating sales-based compensation incentives for reps, nixing doctor speaking fees and tripling an in-house compliance team that checks every submitted receipt--could be negatively impacting its top line at a time when the company's already hurting. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.